A Biotech Pioneer Goes After Big New Game

Even in biotech pioneer Genentech Inc.'s notoriously hard-driving culture, David V. Goeddel had an intensity that few could match. The boyish PhD routinely worked 80-hour weeks and slept at the lab. By his 30th birthday, he had taken over molecular-biology research. For 15 years, he was the industry's most productive scientist. He and his team produced Genentech's first five products, including the heart-attack drug TPA, and published dozens of papers in scientific journals. On his rare vacations, he climbed serious mountains.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.